![]() Triple ICS/LABA/LAMA FDC and dual LABA/LAMA or ICS/LABA FDCs are characterized by specific efficacy/safety profiles in agreement with the level of blood eosinophil count at baseline.ĬOPD ICS LABA LAMA dual bronchodilation network meta-analysis triple therapy. The weighted efficacy/safety profile resulting from SUCRA provided the following ranking in patients with low eosinophil count: ICS/LABA/LAMA>LABA/LAMA≫ICS/LABA whereas in patients with high eosinophil count the ranking was as follows: ICS/LABA/LAMA>LABA/LAMA>ICS/LABA FDC. The treatment ranking was reported via the surface under the cumulative ranking curve analysis (SUCRA).ĭata obtained from 21,909 COPD patients were extracted from the ETHOS, KRONOS, IMPACT, and TRILOGY studies, the only that fulfilled the strict inclusion criteria of this research. either dual LABA/LAMA or ICS/LABA therapies administered at fixed-dose combination (FDC) via the same inhaler device.Ī network meta-analysis was performed to assess the efficacy/safety impact of triple ICS/LABA/LAMA FDC compared with dual LABA/LAMA and ICS/LBA FDCs administered via the same inhaler device in COPD patients. The aim of this study was a quantitative synthesis by considering the studies that directly compared triple ICS/LABA/LAMA vs. Despite adherence to inhaled corticosteroid plus long-acting 2-agonist (ICS/LABA) therapy, 3050 of patients with asthma remain symptomatic and poorly controlled, indicating a clear unmet need in asthma management. Clinical criteria for triple therapy fixed dose-combination (Trelegy Ellipta) and all ICS + LABA FDC inhalers have changed. In some studies comparing triple with dual combination therapies in COPD there might be a possible effect of inhaler bias resulting from different inhaler devices being used in comparator arms. Combining an inhaled corticosteroid (ICS) with a long-acting 2-adrenoceptor agonist (LABA) and a long-acting muscarinic antagonist (LAMA) in a fixed-dose combination (FDC) is a keystone in the treatment of severe forms of chronic obstructive pulmonary disease (COPD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |